Market Size of Subcutaneous Immunoglobulin Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 11.70 Billion |
Market Size (2029) | USD 19.70 Billion |
CAGR (2024 - 2029) | 11.00 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Subcutaneous Immunoglobulin Market Analysis
The Subcutaneous Immunoglobulin Market size is estimated at USD 11.70 billion in 2024, and is expected to reach USD 19.70 billion by 2029, growing at a CAGR of 11% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the market. Some biopharmaceutical companies, such as Merck & Co. Inc. and Eli Lilly and Company, announced clinical trial delays due to the pandemic. For instance, data from ClinicalTrials.gov published in November 2022 indicated that more than 200 interventional oncology studies were suspended due to the COVID-19 pandemic. In addition, 60% of institutions in the United States and 86% in Europe enroll new patients at a lower rate. Therefore, it was observed that the pandemic significantly affected the market growth. However, the market has reached its pandemic nature in terms of research and is expected to witness strong growth.
The major factors attributing to the growth of the market include the increasing use of subcutaneous immunoglobulin for primary immunodeficiency disorders, the increasing geriatric population, and the patient pool.
The increasing burden of immuno-deficiency diseases such as HIV is propelling market growth. For instance, as per the data from NACO published in August 2022, there were around 2.4 million HIV cases in India in 2022. Similarly, the data further stated that the number of HIV patients is still high across various countries such as South Africa and Nigeria, which is believed to contribute significantly to the market growth in the coming years.
Also, as per the Wiley Online Library article published in April 2022, it was indicated that up to 1 in 25,000 people worldwide are born with common variable immunodeficiency (CVID), a genetic disorder that can cripple patients' immune defenses. The data also stated that the overall burden of CVID has been rising in recent years, which is the leading factor responsible for the market growth.
The market players are heavily invested in drug development and approval due to the increasing burden of targeted diseases. For instance, in January 2024, Takeda Pharmaceutical received the United States approval from the US FDA for its HYQVIA to treat a rare, acquired, immune-mediated neuromuscular disorder. Also, in April 2022, Kite Pharma Inc. received product approval from the US FDA for its axicabtagene ciloleucel (Yescarta) for adult patients with large B-cell lymphoma (LBCL). Hence, such approvals and launches of new therapies are expected to propel the market growth.
However, stringent government regulations and the high risk of side effects from the treatment are some factors restraining market growth.
Subcutaneous Immunoglobulin Industry Segmentation
As per the scope of the report, subcutaneous immunoglobulin infusions are given by gradually injecting purified immunoglobulin into the fatty tissue beneath the skin. The subcutaneous immunoglobulin market is segmented by application, end user, and geography. By application, the market is segmented into primary immunodeficiency diseases, secondary immunodeficiency diseases, and other applications. The subcutaneous immunoglobulin market is segmented by end users in hospitals, home care settings, and other end users. The market has been geographically segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report offers the value in USD for the above segments.
By Application | |
Primary Immunodeficiency Diseases | |
Secondary Immunodeficiency Diseases | |
Other Applications |
By End User | |
Hospitals | |
Homecare Settings | |
Other End Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Subcutaneous Immunoglobulin Market Size Summary
The subcutaneous immunoglobulin market is poised for significant expansion, driven by the increasing prevalence of primary immunodeficiency disorders and the growing geriatric population. The market's growth trajectory was initially impacted by the COVID-19 pandemic, which caused delays in clinical trials and reduced patient enrollment rates. However, the market has since rebounded, with strong growth anticipated due to the rising burden of immunodeficiency diseases such as HIV and common variable immunodeficiency (CVID). The demand for subcutaneous immunoglobulin is further bolstered by the increasing approvals of drug candidates and the focus on eliminating viral hepatitis and other related diseases. Despite challenges such as stringent government regulations and potential side effects, the market is expected to thrive, particularly in regions with a high prevalence of these conditions.
North America is projected to lead the subcutaneous immunoglobulin market, supported by a robust healthcare infrastructure, a high number of immunodeficiency disease patients, and an aging population. The region's market growth is also fueled by the rising incidence of cancers, which creates opportunities for healthcare companies. Key players in the market, including Takeda Pharmaceutical Company Limited, Biotest AG, and CSL Behring, are actively contributing to the competitive landscape. Recent developments, such as KORU Medical Systems' agreement to develop a new drug delivery system, highlight the ongoing innovation within the sector. As the demand for immunoglobulin therapies continues to rise, driven by both disease prevalence and technological advancements, the market is set for substantial growth in the coming years.
Subcutaneous Immunoglobulin Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Use of Subcutaneous Immunoglobulin For Primary Immunodeficiency Disorders
-
1.2.2 Increasing Geriatric Population and Patient Pool
-
1.2.3 Rise in Government Funding
-
-
1.3 Market Restraints
-
1.3.1 Stringent Government Regulations
-
1.3.2 High Risk of Side Effects
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION - (Market Size by Value - USD)
-
2.1 By Application
-
2.1.1 Primary Immunodeficiency Diseases
-
2.1.2 Secondary Immunodeficiency Diseases
-
2.1.3 Other Applications
-
-
2.2 By End User
-
2.2.1 Hospitals
-
2.2.2 Homecare Settings
-
2.2.3 Other End Users
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Subcutaneous Immunoglobulin Market Size FAQs
How big is the Subcutaneous Immunoglobulin Market?
The Subcutaneous Immunoglobulin Market size is expected to reach USD 11.70 billion in 2024 and grow at a CAGR of 11% to reach USD 19.70 billion by 2029.
What is the current Subcutaneous Immunoglobulin Market size?
In 2024, the Subcutaneous Immunoglobulin Market size is expected to reach USD 11.70 billion.